Thomas Powles, MD, MBBS, MRCP, discusses the safety and efficacy of enfortumab vedotin-ejfv with pembrolizumab based on data from the phase 3 EV-302/KEYNOTE-A39 trial in patients with previously untreated, locally advanced or metastatic urothelial carcinoma.